Answers are grounded in this paper and cite their sources.
Biopsy triage remains challenging in men with prostate-specific antigen (PSA) levels of 4.0–10.0 ng/mL because multiparametric MRI (mpMRI) may yield equivocal findings and reader-dependent interpretation. Prostate-specific membrane antigen (PSMA) PET/CT may provide complementary molecular information. We evaluated the diagnostic performance and incremental value of the composite P score, which integrates PI-RADS and PRIMARY scores, for detecting clinically significant prostate cancer (csPCa) in the PSA gray zone. This two-center retrospective study included 178 men with PSA 4.0–10.0 ng/mL who underwent mpMRI, 18 F-PSMA PET/CT, and biopsy between January 2021 and December 2024. Junior and senior radiologists independently assigned Prostate Imaging Reporting and Data System (PI-RADS) scores. A single PRIMARY score was assigned for PSMA PET/CT based on two independent nuclear medicine reads, with discrepancies adjudicated. Composite P scores combined each radiologist’s PI-RADS assessment with the PRIMARY score. csPCa was defined as Gleason score ≥ 3 + 4 according to prostate biopsy. Performance was assessed using area under the curve (AUC), net reclassification improvement (NRI), and decision curve analysis (DCA). csPCa was detected in 125/178 patients (70.2%). Compared with PI-RADS alone, the composite P score showed a higher AUC for the junior reader (0.769 vs. 0.661; P = 0.014), while the difference was not significant for the senior reader (0.805 vs. 0.744; P = 0.167). At the threshold of ≥ 3, the composite P score achieved 100% sensitivity (125/125) for both readers. NRI was significant for the junior reader (0.175; P = 0.010) but not for the senior reader. DCA showed higher estimated net benefit than PI-RADS alone across clinically relevant threshold probabilities for both readers. The composite P score showed favorable performance for csPCa in the PSA gray zone. Integrating 18 F-PSMA PET/CT with mpMRI may provide complementary diagnostic information for biopsy triage in selected patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: